April 7, 2022
Distribution of Sotrovimab paused to all HHS Regions
MOBILE, Ala. — On April 5, the Centers for Disease Control and Prevention (CDC) estimated the proportion of COVID-19 cases caused by the Omicron BA.2 variant to be above 50 percent in all U.S. Department of Health and Human Services (HHS) regions. Because of these data, one of the monoclonals that has been available for COVID-19 treatment, Sotrovimab, is not considered effective against BA.2, and its distribution in the United States and territories has been paused.
However, other Emergency Use Authorization (EUA) treatments remain available for distribution. These include Paxlovid (an oral antiviral treatment) and Lagevrio (an alternative oral antiviral for patients for which Paxlovid is not appropriate or accessible).
In addition, Bebtelovimab, an alternative monoclonal antibody therapy that has EUA, is available for treatment of COVID-19. Based upon information about these products, they are likely to be effective against the BA.2 variant.
All treatment delivery sites can continue ordering Paxlovid, Lagevrio, and Bebtelovimab from the authorized distributor by following the existing ordering and reporting procedures.
The Alabama Department of Public Health (ADPH) will continue to closely monitor information from multiple sources regarding surveillance of variants that may impact the use of COVID-19 therapies authorized under EUA. ADPH continues to update providers of these COVID-19 therapeutics and will periodically pause the dashboard in order to keep the list of providers current.
Links to the therapeutics locators are as follows: